



**Figure S4.** PBPK simulations demonstrating the effect of gemfibrozil on the plasma concentrations of montelukast A (perfusion-limited model) and montelukast B (permeability-limited model with OATP1B1 transport, when montelukast  $f_{m,CYP2C8}$  varies between 0.55 and 0.9). Individual trials are shown as thin lines, and their means as thick lines. Blue lines represent the placebo phase and grey lines the gemfibrozil phase.

Circles refer to clinical data from Karonen et al. (2010).